According to a study by BCC Research, the global market for mRNA therapeutics is projected to reach $7.69 billion by 2030, with a compound annual growth rate of -0.04% from 2025 to 2030. The report covers revenue estimates, growth trends, key players, and regional markets, highlighting the potential of mRNA-based treatments for chronic diseases and pandemics like COVID-19.

Key drivers of market growth include the need for rapid vaccine development in response to pandemics, increased awareness of vaccination importance, and investments in mRNA therapeutics research. The market also benefits from the interest in personalized cancer vaccines and the versatility of mRNA drugs for treating genetic and rare diseases.

Notable companies leading the mRNA therapeutics market include Moderna Inc., Pfizer Inc., and AstraZeneca. Emerging startups like Laronde and Generate Biomedicines are leveraging innovative RNA technologies to develop personalized therapies for various diseases, including cancer and autoimmune disorders.

mRNA vaccines instruct the body to produce virus-specific proteins, offering potential treatments for a range of diseases beyond COVID-19. The market is projected to focus on COVID mRNA vaccines through 2030, with North America leading in market share. While opportunities exist in personalized cancer vaccines and mRNA drug development, challenges include production and logistical hurdles for mRNA vaccines.

For further insights into the global market for mRNA therapeutics, interested parties can request a sample or purchase the full report from BCC Research. The report covers market size, growth drivers, disease segments, regional markets, and opportunities in the mRNA therapeutics market. Market leaders, emerging startups, and potential applications of mRNA technologies are also highlighted in the report.

Read more at GlobeNewswire: Small Decline of -0.04% CAGR by 2030